Department of Internal Medicine, Medical Faculty, University of Banja Luka, 78000 Banja Luka, Republic of Srpska, Bosnia and Herzegovina.
Institute of Anatomy, University of Zurich, 8057 Zurich, Switzerland.
Cells. 2021 May 20;10(5):1266. doi: 10.3390/cells10051266.
Fibroblast growth factor-23 (FGF23) appears to be one of the most promising biomarkers and predictors of cardiovascular risk in patients with heart disease and normal kidney function, but moreover in those with chronic kidney disease (CKD). This review summarizes the current knowledge of FGF23 mechanisms of action in the myocardium in the physiological and pathophysiological state of CKD, as well as its cross-talk to other important signaling pathways in cardiomyocytes. In this regard, current therapeutic possibilities and future perspectives are also discussed.
成纤维细胞生长因子 23（FGF23）似乎是心脏病和肾功能正常患者心血管风险的最有前途的生物标志物和预测因子之一，而且在慢性肾脏病（CKD）患者中也是如此。这篇综述总结了 FGF23 在 CKD 的生理和病理生理状态下心肌中的作用机制，以及它与心肌细胞中其他重要信号通路的相互作用的最新知识。在这方面，还讨论了当前的治疗可能性和未来的展望。
